Based on daily diaries, the intensity of nausea reported by patients over the first 3 cycles of chemotherapy was very low (median nausea severity: 1st cycle: 0.56 [P] vs. 0.58 [C], p = 0.61 [Table 4]; 2nd cycle: 0.52 [P] vs. 0.60[C], p=0.36; and 3rd cycle: 0.93 [P] vs. 0.40 [C]; p=0.45, data not shown) with no significant difference between the two arms.
The experiment consisted of three consecutive cycles using four-course rotations with all crops present every year, i.e. 1997 2000 (1st cycle), 2001 2004 (2nd cycle), and 2005 2008 (3rd cycle).
Among the 1829 NHL patients in the source population, 331 (18%) experienced one or more FN events--a total of 479 FN events--during their course of chemotherapy; the number of events, by cycle, occurred as follows: 1st cycle, 128 (27%); 2nd cycle, 64 (13%); 3rd cycle, 67 (14%); 4th cycle, 68 (14%); and 5th or later cycle, 152 (32%).
When tested in lithium-ion batteries, HU-Mn0.33Co0.67C2O4 delivers a high reversible discharge capacity of 924 mAh g−1 at 500 mA g−1 in the 2nd cycle, with 83% capacity retention over 300 cycles.
At a current density of 200 mA g−1, the discharge specific capacities are 876 mAh g−1 at the 2nd cycle and 830 mAh g−1 at the 100th cycle.
The cyclic voltammetry test results proved the effect of this kind of electrocatalysis, and the charge discharge experimental results showed that the polymer has the specific capacity of 422 mAh/g at 2nd cycle and 170 mAh/g at the 44th cycle.
The lithiation and delithiation capacities in the 2nd cycle are 932 and 912(±5) mAh g−1, respectively.
Furthermore, when used as anode materials for sodium-ion batteries, it exhibits an encouragingly high reversible capacity of 720 mAh g− 1 at 50 mA g− 1 during the 2nd cycle.
The specific capacity was still as high as 465.8 mAh g⿿1 at 0.5 C after 600 cycles,with a capacity decay from the 2nd cycle of 0.05% per cycle over 599 cycles.
* In parentheses the number of G3-G4 events ^ 1 patient received C only * 5 patients received Fluorouracil only Focusing on the first two mandatory cycles, 20 patients out of 29 received a full-intensity dose while in 9 patients the 2nd cycle was delayed or modified due to 1 G3 neutropenia and 2 G1-2 leucopoenia, 6 G2-G3 non-haematological toxicities.
At C/10 rate (10 hours per charging cycle), the reversible capacity (the 2nd cycle) of FeWO4-SnO2 core-shell nanorods is up to 1286.9 mAh g−1, much higher than that of FeWO4 nanorods, SnO2 and traditional theoretical results.
